{
    "clinical_study": {
        "@rank": "13218", 
        "arm_group": {
            "arm_group_label": "[14C]-YH4808 200 mg", 
            "arm_group_type": "Experimental", 
            "description": "[14C]-YH4808 200 mg"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the absorption, metabolism, and excretion (AME)\n      kinetics of YH4808 and to determine and characterize metabolites present in plasma, urine,\n      and feces in man following a single dose of [14C] YH4808 200 mg (~100 \u00b5Ci \u00b120 \u00b5Ci)\n      administered as a single oral dose."
        }, 
        "brief_title": "AME Study of [14C]-YH4808 in Healthy Male Subjects", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  clinical laboratory evaluations within the reference range for the test laboratory\n\n          -  negative test for selected drugs of abuse, hepatitis panel and HIV antibody screens\n\n          -  able to comprehend and willing to sign an Informed Consent Form\n\n        Exclusion Criteria:\n\n          -  significant history or clinical manifestation of any significant metabolic, allergic,\n             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,\n             gastrointestinal, neurological, or psychiatric disorder\n\n          -  history of stomach or intestinal surgery or resection that would potentially alter\n             absorption and/or excretion of orally administered drugs\n\n          -  participation in more than 1 other radiolabeled investigational study drug trial\n             within 12 months prior to Check-in\n\n          -  donation of blood from 30 days prior to Screening through Study Completion,\n             inclusive, or of plasma from 2 weeks prior to Screening through Study Completion,\n             inclusive"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01825707", 
            "org_study_id": "YH4808-103"
        }, 
        "intervention": {
            "arm_group_label": "[14C]-YH4808 200 mg", 
            "description": "[14C]-YH4808 200 mg (oral) on day1", 
            "intervention_name": "[14C]-YH4808 200 mg", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 1, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53704"
                }, 
                "name": "Covance Clinical Research Unit"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-YH4808 Following Single Oral Dose Administration in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Covance Clinical Research Unit", 
            "last_name": "Nicholas Siebers, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Maximum observed concentration\nTime to maximum observed concentration\nArea under the concentration-time curve from Hour 0 to the last measurable concentration\nArea under the concentration-time curve extrapolated to infinity\nApparent terminal elimination rate constant\nApparent terminal elimination half-life\nAmount of drug excreted in the urine over the sampling interval\nThe % excreted in urine, where % Excreted = 100 x (Aeu/dose)\nAmount of drug excreted in the feces over the sampling interval\nThe % excreted in feces, where % Excreted = 100 x (Aef/dose)", 
                "measure": "To assess the PK of a single oral dose of [14C] YH4808 200 mg and its metabolites(M3, M8)", 
                "safety_issue": "No", 
                "time_frame": "Day1-Day11"
            }, 
            {
                "measure": "To determine the plasma, whole blood, urine, and feces concentrations of total radioactivity", 
                "safety_issue": "No", 
                "time_frame": "Day1-Day11"
            }, 
            {
                "description": "- Sum of the % excreted in urine and feces", 
                "measure": "To assess mass balance", 
                "safety_issue": "No", 
                "time_frame": "Day1-Day11"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01825707"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To characterize and identify metabolites of [14C]-YH4808 in plasma, urine, and feces", 
                "safety_issue": "No", 
                "time_frame": "Day1-Day11"
            }, 
            {
                "measure": "To determine plasma concentrations of cold YH4808", 
                "safety_issue": "No", 
                "time_frame": "Day1-Day11"
            }, 
            {
                "description": "Clinical laboratory tests\n12-lead ECGs\nPhysical examinations\nVital signs\nAdverse event assessments", 
                "measure": "To assess the safety and tolerability of YH4808", 
                "safety_issue": "Yes", 
                "time_frame": "Day1-Day11"
            }
        ], 
        "source": "Yuhan Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yuhan Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}